{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:46:33Z","timestamp":1787064393798,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.abd.2020.12.007","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T01:59:20Z","timestamp":1622167160000},"page":"458-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Mycosis fungoides and S\u00e9zary syndrome: focus on the current treatment scenario"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5709-092X","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Sanches","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9741-4311","authenticated-orcid":false,"given":"Jade","family":"Cury-Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5819-8038","authenticated-orcid":false,"given":"Rodrigo Martins","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-4908","authenticated-orcid":false,"given":"Denis","family":"Miyashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0655-2821","authenticated-orcid":false,"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2020.12.007_bib0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.abd.2020.12.007_bib0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.det.2015.06.001","article-title":"Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma","volume":"33","author":"Olsen","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.abd.2020.12.007_bib0015","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2013.09.007","article-title":"Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium","volume":"70","author":"Kadin","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.semdp.2019.07.010","article-title":"Cutaneous manifestations of adult T-cell leukemia\/lymphoma","volume":"37","author":"Miyashiro","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.abd.2020.12.007_bib0025","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome - Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.abd.2020.12.007_bib0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fonc.2019.00260","article-title":"Skin Directed Therapy in Cutaneous T-Cell Lymphoma","volume":"9","author":"Tarabadkar","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/cco.2019.01.02","article-title":"Systemic therapy of cutaneous T-cell lymphoma (CTCL)","volume":"8","author":"Alpdogan","year":"2019","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2020.12.007_bib0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0190-9622(90)70112-U","article-title":"Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients","volume":"22","author":"Zackheim","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0065","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0070","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/09546634.2017.1294728","article-title":"Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series","volume":"28","author":"Lewis","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2020.12.007_bib0075","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.abd.2020.12.007_bib0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0085","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/jdv.12254","article-title":"Localized conventional radiotherapy in the treatment of Mycosis Fungoides: our experience in 100 patients","volume":"28","author":"Piccinno","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.12.007_bib0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"International Lymphoma Radiation Oncology G. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.abd.2020.12.007_bib0095","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0360-3016(98)00218-1","article-title":"Radiotherapy for unilesional mycosis fungoides","volume":"42","author":"Micaily","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.abd.2020.12.007_bib0100","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0360-3016(97)00127-2","article-title":"Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)","volume":"38","author":"Quir\u00f3s","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.abd.2020.12.007_bib0105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/09546634.2018.1487525","article-title":"Retinoic acid receptor agonist as monotherapy for early-stage mycosis fungoides: does it work?","volume":"30","author":"Amitay-Laish","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2020.12.007_bib0115","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.det.2015.05.007","article-title":"The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma","volume":"33","author":"Huen","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.abd.2020.12.007_bib0120","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/jdv.16567","article-title":"Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicenter study","volume":"34","author":"Nikolaou","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.12.007_bib0125","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-3083.2011.04011.x","article-title":"Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma","volume":"26","author":"Husken","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.12.007_bib0140","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/jdv.14366","article-title":"Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma","volume":"31","author":"Schiller","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.12.007_bib0145","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.det.2015.05.008","article-title":"The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma","volume":"33","author":"Spaccarelli","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.abd.2020.12.007_bib0150","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cncr.10706","article-title":"Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma","volume":"95","author":"Chiarion-Sileni","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.abd.2020.12.007_bib0155","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.abd.2020.12.007_bib0160","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.abd.2020.12.007_bib0165","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0170","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2133.2000.03601.x","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy","volume":"143","author":"Coors","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0180","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0190-9622(84)80323-0","article-title":"The treatment of Sezary syndrome","volume":"10","author":"Winkelmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0185","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00000421-198410000-00012","article-title":"Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone","volume":"7","author":"Case","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.abd.2020.12.007_bib0195","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0200","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.det.2015.05.009","article-title":"Methotrexate and Pralatrexate","volume":"33","author":"Wood","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.abd.2020.12.007_bib0205","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0210","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0215","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3109\/10428194.2015.1014360","article-title":"Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma","volume":"56","author":"Kim","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.abd.2020.12.007_bib0220","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0225","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.abd.2020.12.007_bib0230","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2020.12.007_bib0235","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2020.12.007_bib0245","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0250","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.det.2015.05.011","article-title":"Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sezary Syndrome","volume":"33","author":"Zic","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.abd.2020.12.007_bib0255","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.2019000765","article-title":"Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome","volume":"134","author":"Gao","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.abd.2020.12.007_bib0260","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)","volume":"167","author":"Whittaker","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2020.12.007_bib0265","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.abd.2020.12.007_bib0270","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059621001161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059621001161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:40:13Z","timestamp":1759794013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059621001161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0365059621001161"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2020.12.007","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycosis fungoides and S\u00e9zary syndrome: focus on the current treatment scenario","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}